Ark Biopharmaceutical

Ark Biopharmaceutical (爱科百发, Ark Biosciences) is a Shanghai-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for respiratory diseases and pediatric conditions. Its pipeline includes AK0529 (ziresovir) for respiratory syncytial virus (RSV) infection, AK0901 for ADHD, AK3280 for idiopathic pulmonary fibrosis, AK0610 for RSV prevention, and AK0705 for COPD. The company is a portfolio company of Qiming Venture Partners and was added to the API Evangelist network as a stub for enrichment. As a drug-development company it publishes a corporate website, R&D pipeline, and news center, but exposes no public developer platform, API, or technical integration surface at this time.

Ark Biopharmaceutical is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Biotechnology, and Drug Development.

Ark Biopharmaceutical’s developer surface includes engineering blog and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub

3.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiopharmaceuticalPharmaceuticalsBiotechnologyDrug DevelopmentRespiratoryPediatricsHealthcareChina

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 3.8/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/arkbiosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 3

The organization behind the API

Website

Website

About

About

Blog

Blog

Source (apis.yml)

aid: arkbiosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/arkbiosciences.png
name: Ark Biopharmaceutical
description: Ark Biopharmaceutical (爱科百发, Ark Biosciences) is a Shanghai-based clinical-stage biopharmaceutical company focused
  on the discovery and development of innovative therapies for respiratory diseases and pediatric conditions. Its pipeline
  includes AK0529 (ziresovir) for respiratory syncytial virus (RSV) infection, AK0901 for ADHD, AK3280 for idiopathic pulmonary
  fibrosis, AK0610 for RSV prevention, and AK0705 for COPD. The company is a portfolio company of Qiming Venture Partners
  and was added to the API Evangelist network as a stub for enrichment. As a drug-development company it publishes a corporate
  website, R&D pipeline, and news center, but exposes no public developer platform, API, or technical integration surface
  at this time.
url: https://raw.githubusercontent.com/api-evangelist/arkbiosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Biotechnology
- Drug Development
- Respiratory
- Pediatrics
- Healthcare
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/arkbiosciences-domain-security.yml
- type: Website
  url: https://www.arkbiosciences.com
- type: About
  url: https://www.arkbiosciences.com/about/
- type: Blog
  url: https://www.arkbiosciences.com/news/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Ark Biopharmaceutical

Kin Score

Security Posture 1

Arkbiosciences Domain Security

Resources

Access & Security 1

Company 3

Source (apis.yml)